IBRXImmunityBio, Inc.
$10.51+285% 1Y
$10.51
$1.9852 weeks$11.55
Is the price fair?
What IBRX's price assumes
ImmunityBio, Inc. did not earn a profit over the last twelve months, so it has no trailing P/E and the price is measured against sales instead: 49.3× revenue.
49.3
Price / sales · no P/E: the last twelve months did not end in a profit
Details›
- EV / EBIToperating margin −152%: the multiple describes the denominator
- not meaningful
- Market capitalisation
- $8.16B
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
On our screens:Most shorted stocks